09 July 2020
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) »
09 July 2020
IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) »
10 June 2020
Our latest release: MERCURY™ v3.0
We are excited to provide you with important information regarding the release of a new version (v3.0) of MERCURY™. This updated version of MERCURY has a number of changes and improvements designed to enhance data analysis capabilities and the user experience.
MERCURY v3.0 has (…) »
13 April 2020
IntegraGen announces the company’s MERCURY™ cloud-based analytical software tool has achieved Conformité Européenne (CE) marking. This registration enhances the ability for IntegraGen sell MERCURY throughout the European Union (EU). MERCURY is utilized by researchers and clinicians to assist with the analysis of sequencing data derived from small (…) »
03 April 2020
+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year
IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.
Operating (…) »
31 March 2020
IntegraGen is following the French Government’s recommendations and precautionary measures for COVID-19. As an essential supplier of genomic research services, we are committed to meeting the needs of our customers while also making every effort to protect the health and well-being of our employees and their families.
We have undertaken (…) »
26 March 2020
IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…) »
17 March 2020
Dear IntegraGen partner and customer,
We value your well-being and understand that the entire community is impacted by the novel coronavirus (COVID-19) outbreak. This is why we are committed to providing consistent and timely support so your important work is not interrupted.
IntegraGen is closely monitoring guidance from health authorities (…) »
11 March 2020
IntegraGen announces the renewal of its partnership agreement with the Institut Pasteur until December 2021 related to high-throughput sequencing operations for microbiology activities carried out at the Institut Pasteur.
Click here to view press release.
12 January 2020
IntegraGen announced today its unaudited business figures for the year 2019.
2019 revenue amounted to 8.3 M € versus 6.9 M € in 2018, an increase of 20% over 12 months. This performance highlights an acceleration from the high growth level of 15% reported for the first half of 2019. (…) »